BCL2L10

Bcl-2-like protein 10 · Q9HD36 · BCL2L10 on Sugi Atlas →

1,006 patent compounds predicted against BCL2L10, 790 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gambogic Acid (SCHEMBL134152)	1.00	1/20
Gambogic Acid (SCHEMBL149213)	1.00	1/20
Gambogic Acid (SCHEMBL3857525)	1.00	1/20
Gambogic Acid (SCHEMBL7946944)	1.00	1/20
Gambogic Acid (SCHEMBL7947021)	1.00	1/20
Gambogic Acid (SCHEMBL12025351)	1.00	1/20
Gambogic Acid (SCHEMBL12025387)	1.00	1/20
Gambogic Acid (SCHEMBL12025441)	1.00	1/20
Gambogic Acid (SCHEMBL12026374)	1.00	1/20
Gambogic Acid (SCHEMBL12045553)	1.00	1/20
Gambogic Acid (SCHEMBL12045554)	1.00	1/20
Gambogic Acid (SCHEMBL12751296)	1.00	1/20
Gambogic Acid (SCHEMBL12859660)	1.00	1/20
Gambogic Acid (SCHEMBL13613351)	1.00	1/20
Gambogic Acid (SCHEMBL13685811)	1.00	1/20
Gambogic Acid (SCHEMBL13685812)	1.00	1/20
Gambogic Acid (SCHEMBL1150670)	0.93	1/20
Gambogic Amide (SCHEMBL12751295)	0.89	1/20
SCHEMBL12045507	0.88	1/20
SCHEMBL12045561	0.88	1/20

Clinical trials — most relevant to BCL2L10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?	PHASE4	COMPLETED
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission	PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)	PHASE1/PHASE2	COMPLETED
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL	PHASE2	RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)	PHASE2	COMPLETED
Combination Immunotherapy Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS	PHASE1	RECRUITING
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases	PHASE1	COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings	nan	ACTIVE_NOT_RECRUITING
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BCL2L10 binder may also engage these)

Protein	Name	Similarity
Q9Z0F3	—	0.985	Q9Z0F3 →
Q562E7	—	0.981	Q562E7 →
Q99M66	—	0.981	Q99M66 →
Q86XR2	—	0.980	Q86XR2 →
Q6PDZ2	—	0.980	Q6PDZ2 →
Q8K330	—	0.979	Q8K330 →
A1L3T7	—	0.979	A1L3T7 →
A0PJX8	—	0.979	A0PJX8 →
Q90ZN1	—	0.979	Q90ZN1 →
Q15572	—	0.978	Q15572 →
O75064	—	0.978	O75064 →
STRA6	Receptor for retinol uptake STRA6	0.978	landscape →
O14669	—	0.978	O14669 →
Q9JL70	—	0.977	Q9JL70 →
Q9H7M6	—	0.977	Q9H7M6 →
Q91828	—	0.977	Q91828 →
Q8NFK1	—	0.977	Q8NFK1 →
Q9EQR6	—	0.977	Q9EQR6 →
Q5R7B4	—	0.976	Q5R7B4 →
Q6ZQA0	—	0.976	Q6ZQA0 →
A3KN25	—	0.976	A3KN25 →
Q0V8E7	—	0.976	Q0V8E7 →
Q62227	—	0.976	Q62227 →
P27106	—	0.976	P27106 →
D3ZVB0	—	0.976	D3ZVB0 →
P58660	—	0.976	P58660 →
Q5PNP6	—	0.976	Q5PNP6 →
Q3U0V2	—	0.976	Q3U0V2 →
Q7TNI2	—	0.976	Q7TNI2 →
Q80VA5	—	0.976	Q80VA5 →